Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Polaris Group

Market Cap 11.57B 365M 317M 292M 274M 512M 34.98B 522M 3.49B 1.35B 16.86B 1.37B 1.34B 58.63B P/E Ratio 2024
-13.6x
P/E Ratio 2025 -6.1x
Enterprise Value 12.08B 382M 331M 305M 286M 534M 36.54B 546M 3.64B 1.41B 17.61B 1.43B 1.4B 61.25B EV / Sales 2024
318x
EV / Sales 2025 603x
Free-Float
33.35%
Yield 2024 *
-
Yield 2025 -
1 day+3.46%
1 week+2.67%
Current month-0.37%
1 month-20.41%
3 months-54.71%
6 months-57.37%
Current year-56.75%
1 week 12.65
Extreme 12.65
13.6
1 month 12.65
Extreme 12.65
18.15
Current year 12.65
Extreme 12.65
35.95
1 year 12.65
Extreme 12.65
44.55
3 years 12.65
Extreme 12.65
91.1
5 years 12.65
Extreme 12.65
232
10 years 9.5
Extreme 9.5
232
Manager TitleAgeSince
Director of Finance/CFO - 2019-02-28
Chief Operating Officer - 2019-01-31
Chief Executive Officer - 2014-04-30
Director TitleAgeSince
Chairman 64 2014-11-23
Director/Board Member - 2020-02-24
Director/Board Member - 2020-01-02
Change 5-day change 1-year change 3-year change Capi.($)
+3.46%+2.67%-69.15%-85.11% 365M
-0.08%+1.19%-15.77%-12.53% 42.96B
+3.50%-4.15%+265.85%+484.30% 31.73B
-0.61%-3.11%+14.00%-12.36% 30.22B
-1.27%-7.02%-0.82%+20.47% 28.94B
-0.66%-5.84%+7.59%+12.76% 23.87B
+2.01%+3.57%+57.15%+128.55% 13.57B
-0.28%-1.17%+6.19%+7.72% 12.96B
+2.77%-1.48% - - 13.39B
+0.68%-1.74%+103.98%+81.60% 12.2B
Average +0.95%-1.76%+41.00%+69.49% 21.02B
Weighted average by Cap. +0.50%-2.39%+53.03%+92.27%

Financials

2024 2025
Net sales 107M 3.38M 2.93M 2.7M 2.53M 4.73M 324M 4.83M 32.25M 12.49M 156M 12.69M 12.41M 542M 40.6M 1.28M 1.11M 1.03M 961K 1.8M 123M 1.83M 12.24M 4.74M 59.19M 4.81M 4.71M 206M
Net income -2.5B -79.05M -68.6M -63.23M -59.25M -111M -7.57B -113M -754M -292M -3.65B -297M -290M -12.69B -3.93B -124M -108M -99.23M -92.98M -174M -11.88B -177M -1.18B -458M -5.73B -466M -456M -19.91B
Net Debt 9.19M 290K 252K 232K 218K 407K 27.8M 415K 2.77M 1.07M 13.4M 1.09M 1.07M 46.59M 517M 16.33M 14.17M 13.06M 12.24M 22.86M 1.56B 23.34M 156M 60.32M 754M 61.29M 59.97M 2.62B
Logo Polaris Group
The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Company’s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.
Employees
-
Date Price Change Volume
26-06-11 13.45 NT$ +3.46% 1,490,130
26-06-10 13.00 NT$ -1.14% 1,101,474
26-06-09 13.15 NT$ 0.00% 1,331,633
26-06-08 13.15 NT$ -1.87% 1,520,321
26-06-05 13.40 NT$ +2.29% 2,101,496
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. 6550 Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!